CN1067244C - Notoginsenoside powder injection - Google Patents
Notoginsenoside powder injection Download PDFInfo
- Publication number
- CN1067244C CN1067244C CN96101652A CN96101652A CN1067244C CN 1067244 C CN1067244 C CN 1067244C CN 96101652 A CN96101652 A CN 96101652A CN 96101652 A CN96101652 A CN 96101652A CN 1067244 C CN1067244 C CN 1067244C
- Authority
- CN
- China
- Prior art keywords
- injection
- notoginsenoside
- powder
- water
- powder injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002347 injection Methods 0.000 title claims abstract description 15
- 239000007924 injection Substances 0.000 title claims abstract description 15
- 239000000843 powder Substances 0.000 title claims abstract description 14
- 229930189092 Notoginsenoside Natural products 0.000 title claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 abstract description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 230000002107 myocardial effect Effects 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 230000036284 oxygen consumption Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 210000004720 cerebrum Anatomy 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 241000218628 Ginkgo Species 0.000 description 3
- 235000011201 Ginkgo Nutrition 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000009692 xuesetong Substances 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- INLFWQCRAJUDCR-LYLBMTSKSA-N spirostane group Chemical group [C@@H]12C[C@@H]3O[C@]4(CC[C@@H](C)CO4)[C@@H](C)[C@@H]3[C@@]1(C)CC[C@H]1[C@H]2CCC2CCCC[C@]12C INLFWQCRAJUDCR-LYLBMTSKSA-N 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a special dosage form medicine for curing angiocardiopathy and cerebrovascular disease. The notoginsenoside powder injection consists of notoginsenoside and water soluble medicinal supplementary material for injection, and the notoginsenoside content is 50-99.5 wt% except medicinal supplementary material or water. The powder injection of the present invention has the advantages of convenient transportation, long storage period, good stability and high quality compared with water injection products, and can be produced in large scale. The powder for injection contains notoginsenoside as active component, and has effects of promoting blood circulation for removing blood stasis, reducing myocardial oxygen consumption, improving angina pectoris, dissolving cerebral thrombosis, increasing cerebral blood oxygen partial pressure and improving cerebrum.
Description
The present invention relates to a kind of medicine that is used for the treatment of the special form of cardiovascular and cerebrovascular disease.
That Chinese patent application CN1085091 (application number 93105878) discloses is a kind of " with Folium Ginkgo and contain the Saponin plant make the DANFU square preparation of preventing and treating cardiovascular and cerebrovascular vessel disease ", is to be folk prescription or the compound preparation that primary raw material is made with the extraction and the separator of Folium Ginkgo dried powder, Folium Ginkgo and the total Saponin of some steroidal that contains the spirostane skeleton.Extraction process adopts polar solvent and in conjunction with adsorption method of separation and carbon dioxide supercritical fluid extraction partition method.For solving the bitterness of preparation, adopt the molecular capsule technology.
Radix Notoginseng is the rare Chinese medicine of Yunnan specialty, just to be used for the obstruction of heart-QI unhappy etc. from ancient times, recent studies confirms that arasaponin is one of its effective ingredient, and the seventies is opened and cheated research and development arasaponin injection (XUESAITONG), and XUESAITONG ZHUSHEYE has been subjected to the welcome of extensive patients now.But along with output constantly enlarges, quality problems also occur now and then, and aqueous injection freezes in the north winter, and inconvenience is used, intramuscular injection pain, and patient is reluctant to use.These all are to enlarge to use to be provided with obstacle.
Purpose of the present invention is intended to overcome the deficiencies in the prior art, and a kind of convenient transportation is provided, the notoginsenoside powder injection that storage period is long.
Notoginsenoside powder injection of the present invention is made up of arasaponin and water for injection dissolubility pharmaceutic adjuvant, and the content of arasaponin is 50-99.5% (percentage by weight), and surplus is pharmaceutic adjuvant or moisture content.
Water for injection dissolubility pharmaceutic adjuvant of the present invention is: organic or biochemical adjuvants such as aminoacid, glucose, lactose, mannitol, polyvinylpyrrolidone, low molecular dextran also can be inorganic salts such as sodium chloride, calcium chloride, calcium gluconate, phosphate.
Injectable powder convenient transportation of the present invention, storage period is long, and than the aqueous injection good stability of products, the quality height can be mass-produced, and the gained injection is through check behind the adding water for injection, and every index all meets the requirements.This injectable powder is active component with the arasaponin, has blood circulation promoting and blood stasis dispelling, reduces myocardial oxygen consumption, improves angina pectoris, dissolving cerebral thrombosis, increase brain blood oxygen pressure and improve the effect of brain.
Embodiment:
1, at 100 grades being raw material with the arasaponin in going to the workshop, the water that adds 5-20 times of raw material weight, under 50-80 ℃ condition, add 5% low molecular dextran, adjusting PH is 5.5-8.5, solution is through aseptic filtration, aseptic spray drying airtightly promptly gets required injectable powder raw material, is distributed into 2ml cillin bottle 100mg, roll lid, packing gets product.
2, in the back workshop section that produces the arasaponin workshop (refining workshop section), to make with extra care workshop section and be placed in 100 grades, before separating out arasaponin, add the adjuvant of required ratio, regulate pH value with operation in go to the workshop (space), through aseptic filtration, separate out arasaponin with the menstruum method, sucking filtration, dry below 100 ℃, promptly get powder pin raw material (also available spray drying method), further be distributed into 200mg in the 5ml cillin bottle, roll lid, packing gets product.
3, the above-mentioned arasaponin 100g that makes is dissolved in the 700ml water for injection, add 3gNaH
2PO
4And 2gNa
2HPO
4, be heated to 50-60 ℃ of dissolving, filter, be distributed into every, 0.65ml, lyophilization, promptly gets the lyophilized injectable powder that every ampoule contains 100mg (effective ingredient) at sealing by fusing.
Claims (1)
1, a kind of notoginsenoside powder injection, it is characterized in that forming with the water solublity pharmaceutic adjuvant by arasaponin and injection, the content of described arasaponin is (percentage by weight) 50-99.5%, surplus is a pharmaceutic adjuvant, and described pharmaceutic adjuvant is aminoacid, glucose, lactose, mannitol, polyvinylpyrrolidone, low molecular dextran, sodium chloride, calcium gluconate or calcium phosphate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96101652A CN1067244C (en) | 1996-02-17 | 1996-02-17 | Notoginsenoside powder injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96101652A CN1067244C (en) | 1996-02-17 | 1996-02-17 | Notoginsenoside powder injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1157720A CN1157720A (en) | 1997-08-27 |
| CN1067244C true CN1067244C (en) | 2001-06-20 |
Family
ID=5117170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96101652A Expired - Lifetime CN1067244C (en) | 1996-02-17 | 1996-02-17 | Notoginsenoside powder injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1067244C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6500468B1 (en) * | 2002-01-03 | 2002-12-31 | Farlong Pharmaceutical, Inc. | Panax notoginsenoside composition |
| CN1329037C (en) * | 2003-05-07 | 2007-08-01 | 丽珠集团利民制药厂 | Intravenous inject contg. pseudo-ginseng total saponin and its prodn. method |
| CN100339085C (en) * | 2003-09-23 | 2007-09-26 | 天津天士力制药股份有限公司 | Combination of Chinese traditional medicine for curing cardiovascular and cerebrovascular diseases |
| CN1771978B (en) * | 2004-11-09 | 2011-06-08 | 成都华神集团股份有限公司制药厂 | Notoginseng triol-saponin composition and its preparation and use |
| CN100406018C (en) * | 2005-06-17 | 2008-07-30 | 张晴龙 | A nanometer 'Xue Sai Tong' injection and preparation method thereof |
| CN100484517C (en) * | 2006-06-28 | 2009-05-06 | 昆明制药集团股份有限公司 | A lyophilized powder for injection containing Notoginseng radix total saponin with good appearance and shatter resistance, and its preparation method |
| CN101224228B (en) * | 2007-01-16 | 2013-06-19 | 昆明制药集团股份有限公司 | Panax notoginseng saponins freeze-dried powder injection and preparing method thereof |
| CN103536610B (en) * | 2013-01-09 | 2015-03-11 | 上海中医药大学 | Medical application of notoginsenoside Fc |
-
1996
- 1996-02-17 CN CN96101652A patent/CN1067244C/en not_active Expired - Lifetime
Non-Patent Citations (3)
| Title |
|---|
| 中国急救医学，15(4) 1995.1.1 徐琳等人"血塞通注射液颈内动脉注射治疗脑梗塞所致偏瘫35例" * |
| 云南医药，13(5) 1992.1.1 邓士贤"云南几种中草药的药理作用及应用 " * |
| 云南医药，13(5) 1992.1.1 邓士贤"云南几种中草药的药理作用及应用 ";中国急救医学，15(4) 1995.1.1 徐琳等人"血塞通注射液颈内动脉注射治疗脑梗塞所致偏瘫35例" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1157720A (en) | 1997-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068682A (en) | Chinese medicinal composition for treating digestive system diseases and preparation method thereof | |
| CN1067244C (en) | Notoginsenoside powder injection | |
| CN107319086A (en) | A kind of matrimony vine spun gold emperor chrysanthemum pressed candy and preparation method thereof | |
| CN102671178B (en) | Preparation method of Chinese medicinal composition for treating nephrotic syndrome and uremia and application thereof | |
| CN101190906B (en) | Method for preparing carthamin yellow carthamus B and application thereof | |
| CN109528998A (en) | A kind of gynecological external use decontamination drug and preparation method thereof | |
| CN1679701A (en) | Medicinal preparation containing notoginseng and saflower for treating cardio-cerebral blood diseases and its preparing method | |
| CN102293984B (en) | Xingnaojing freeze-drying quick release preparation and preparation method and application thereof | |
| CN113144076A (en) | Traditional Chinese medicine composition for treating myocarditis | |
| CN100455302C (en) | Danshen freeze-drying injection for treating cardiovascular and cerebrovascular diseases and preparation thereof | |
| CN101176750A (en) | Chaihuang freeze dried injection and preparation method thereof | |
| CN110585260A (en) | Single-ingredient freeze-dried powder and preparation method thereof | |
| CN100462082C (en) | Erigeron breviscapus ketone ester and its injection preparation process | |
| CN1679703A (en) | Medicinal preparation containing notoginseng and ginkgo leaf for cardio-cerebral blood vessel diseases and its preparing method | |
| CN1559523A (en) | Naodesheng soft capsule and its preparation method | |
| CN110420320A (en) | A kind of Chinese medicine composition for removing gout pathogenesis basis | |
| CN1274320C (en) | Notoginseng ginkgo health care food and its preparation method | |
| CN101574454B (en) | Restoration traditional Chinese medicine | |
| CN108210877A (en) | Treat the preparation method of cardiopathic pharmaceutical composition | |
| CN1935183A (en) | Chinese medicine compound preparation and its preparing method | |
| CN105055835A (en) | Traditional Chinese medicine composition used for treating female menopausal syndrome | |
| CN109833360A (en) | A kind of preparation method of herbal composite and preparation with antipyretic effect | |
| CN115120657A (en) | Traditional Chinese medicine composition for anti-permeability dilatation in shock-resistant period of burn, pharmaceutical preparation and preparation method | |
| CN1935234A (en) | Chinese medicine injection preparation and its preparing method | |
| CN1935230B (en) | Chinese medicine injection preparation and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: KUNMING MEDICINE GROUP STOCK CO., LTD. Free format text: FORMER NAME OR ADDRESS: KUNMING MEDICINE STOCK CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Patentee after: Kunming Pharmaceutical Group Co., Ltd Patentee before: Kunming Pharmaceutical Co., Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: KPC CO., LTD. Free format text: FORMER NAME: KUNMING PHARMACEUTICAL INDUSTRY GROUP CORP., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 650106 Kunming science and Technology Industrial Development Zone, Yunnan Province Road No. 166 Patentee after: Kun Yao Group Plc Address before: 650100, seven kilometers west of Kunming City, Yunnan Province Patentee before: Kunming Pharmaceutical Industry Group Corp., Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20010620 |
|
| EXPY | Termination of patent right or utility model |